Business Wire

CA-LASERFICHE

28.11.2023 16:01:35 CET | Business Wire | Press release

Share
Healthcare Leaders Cite Automation, Worker Burnout as Top Drivers of Technology Integrations, MGMA and Laserfiche Study Finds

New research by Medical Group Management Association (MGMA) and Laserfiche — the leading SaaS provider of intelligent content management and business process automation — reveals that most healthcare organizations’ top priorities when considering integrative technologies are the elimination of manual work, mitigation of clinician/worker burnout and time savings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128977000/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Discover the opportunities and challenges for medical practice leaders in evaluating their platforms for workflow, electronic forms, document and records management and more. (Graphic: Business Wire)

“The healthcare industry has been disrupted by the growth of virtual visits, expectations for more personal, faster access to patients’ clinical results and care, plus the rise of AI,” said Grace Nam, strategic solutions manager, healthcare, at Laserfiche. “These trends have created a burgeoning challenge of managing, processing and leveraging an inundation of data that require cross-functional collaboration, and often include external organizations like labs and other physicians.”

The study surveyed medical practice administrators, physicians, billing and coding leaders and health information technology (HIT) workers for their views on electronic health records (EHR) or practice management (PM) systems, business automation and more. According to the report, most healthcare organizations are not looking to make a switch to a new EHR or PM system and nearly 80% of respondents rated their current EHR system as “very good” or “good.” However, when it came time to rate EHR systems’ individual attributes, those ratings dropped. Only half of respondents rated their EHR systems “very good” or “good” at saving time; 47% said they were very good or good at saving money; and only 40% said they were very good or good at mitigating clinician/worker burnout.

“Time-strapped organizations need integrated technologies to extract value from data without adding to the long list of manual tasks for already overwhelmed employees,” Nam added. “Investments in systems that enable business process automation while facilitating information governance are critical to healthcare organizations’ ability to leverage data and retain employees while providing a modern patient experience. Supporting the back office — including medical billing and coding, and working with third-party insurance companies — to boost speed and accuracy will be critical for on-time payments that impact revenue.”

“The business of healthcare and its future are tied directly to the ability to manage and make decisions based on data to support high-quality patient care,” the report states. “As the amount of data generated in healthcare grows about 47% a year, the need to manage the growing volumes of records in a secure, compliant fashion is unmistakable.”

To download a copy of the Intelligent Automation in Healthcare report, visit https://info.laserfiche.com/resource/intelligent-automation-healthcare.

To learn more about Laserfiche solutions for the healthcare industry, visit laserfiche.com/solutions/healthcare.

About Laserfiche

Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through workflows, e-forms, document management, integrations and analytics, the Laserfiche® platform centralizes information, structures clinical data and streamlines back-office processes so that healthcare professionals can focus on providing the highest standard of patient care.

For over 30 years, Laserfiche has served organizations in the healthcare industry as a trusted system for document and records management, enabling medical professionals to quickly retrieve records when needed, with robust security and compliance tools to support HIPAA compliance and patient confidentiality. By streamlining paperwork, information and data using digital forms and automated workflows, Laserfiche allows administration, clinicians and physicians to eliminate repetitive manual tasks, gain visibility into operations, support a holistic approach to patient care and focus on improving patient outcomes. Prebuilt solutions and integrations with industry-specific and common business applications further extend organizations’ digital transformation initiatives.

Today, Laserfiche’s cloud-first approach incorporates innovations in machine learning and AI, supporting healthcare organizations in empowering staff, streamlining the patient experience, supporting HIPAA compliance and providing the best possible patient experience.

Learn more at laserfiche.com/solutions/healthcare.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231128977000/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye